Strong growth in 2008 for OM Pharma, the Swiss-based international bio-pharma group

Meyrin/Geneva, January 7th, 2009.

The business results of the OM Pharma group in 2008 have reached an all time high, with a consolidated turnover of 131.7 million CHF (unaudited results), an 18 % increase with respect to 2007. This represents worldwide sales of OM Pharma products of 240 million CHF.

Among the record sellers, Broncho-Vaxom®, the immunostimulating bacterial extract aimed at preventing respiratory tract infections, reached 105 million CHF in local sales, a 21% increase with close to 120 million capsules being bought worldwide. The revenues of the other bacterial extract Uro-Vaxom®, prescribed for the prevention of urinary tract infections, totalled 17.3 million CHF.

To strengthen the corporate identity of the company, the two subsidiaries OM PORTUGUESA in Lisbon and OM PERU in Lima have now been renamed since January 2009 as OM Pharma S.A., like the parent Swiss company in Geneva.

Should you need any further information, please contact Dr. Philippe Meuwly, Head of Information and Communications of the OM Pharma group in Geneva, philippe.meuwly@ompharma.com, +4122 783 13 50.